Quick Contact
+973 17 113 333
+973 17 113 270
Disable Preloader
Health Investment Center
Your Opinion
عربى
Login
Sitemap
عربي
Home
ABOUT US
Overview
Our Vision, Mission and Values
Message from Head of SCH
Message from NHRA CEO
NHRA Organizational Chart
NHRA Strategy 2021 - 2025
NHRA Annual Report
NHRA Governance Report
NHRA Customer Service Charter
DEPARTMENTS / SERVICES
HCP (Health Care Professionals)
MDR (Medical Device Regulation)
Accreditation
HFR (Health Facilities Regulation)
Clinical Trials (CT) & Continuous Professional Development (CPD)
LAU (Legal Affairs Unit)
Pharmacy & Pharmaceutical Product Regulation
Medical Complaints and Investigation Section
MEDIA
Press Release
Photo Gallery
Video Gallery
Publications
Newsletter
Announcements
Health News
OPEN DATA
Licensed Professionals
Licensed Medicines & Health Products
Licensed Medical Devices and Authorized Representiatives
Approved Clinical Trials
Licensed Facilities
Licensed Pharmacies
Approved CPD Activities
Annual Report
Legal Affairs Unit
ENHRA APPLICATION
Munshaat
Mehan
CONTACT US
Contact Us
Departments Contacts
Press Release
Home
Media
Press Release
Photo Gallery
Video Gallery
Publications
Newsletter
Announcements
Health News
ALERT: Drug Recall - Cefuzime 500mg Tablets
24 February 2019
Circular Released by NHRA on Sunday, 24 February 2019.
SUBSCRIBE TO OUR NEWSLETTER
This field is required
This field is required
Please enter a valid email
© Copyrights 2024. National Health Regulatory Authority, Kingdom of Bahrain, All Rights Reserved.
What do you think of
NHRA Services?
Excellent
Good
Bad
Can be Improved
No Comments
VOTE
VIEW RESULTS
BACK
